Chewy Looks Cheap on Sales, but the Downgrade Exposes a Growth-Multiple Problem

Chewy reported a stronger-than-expected quarter on September 9 — sales up 7.3% to $3.33 billion, a beat — and the stock fell about 10% anyway. Two days later came another drop on a second analyst downgrade in as many sessions, this one from JPMorgan. Headlines blame "macro headwinds." That is the polite way of saying the market is finally repricing Chewy as what the factor data has said it is all year: a well-run, low-growth company still carrying a growth-stock multiple.

The downgrade did not invent a problem. It caught up to one that has been visible in the numbers for months. Chewy is down roughly 40% year to date, and the 52-week range tells the story of a multiple deflating: the stock touched $40.55 a year ago and now trades around $20, down about 15% in the last five sessions alone. JPMorgan cut it from Overweight to Neutral with a $24 target, down from $29, joining Evercore ISI, which had already trimmed it to In Line at $25. Neither call says the company is broken. JPMorgan's analyst, Doug Anmuth, explicitly said Chewy is still winning share, growing two to three times faster than the broader pet market. The concern is narrower and more damaging to the valuation: organic growth is stuck.

So count the mismatch. On the surface Chewy looks cheap — a price-to-sales ratio of roughly 0.6x on trailing revenue, and an EV/EBITDA near 17x. But those are the wrong rulers for a business with thin margins. The relevant one is forward earnings, and Chewy trades at about 33x forward earnings while organic net sales grow just 5.7% year over year. That is a growth multiple paying up for a company whose own guidance assumes nothing better: management narrowed full-year organic growth to 5.5%–6.3% and said it is not assuming a consumer recovery. There is nothing wrong with growing 6%; there is something wrong with pricing that growth like it is 20%.

The quarter made the gap plain. The adjusted EBITDA margin of 6.8% beat guidance, but management attributed "substantially all" of the outperformance to timing and one-time benefits — an earlier-than-expected tariff refund, shifted rebates, gift-card breakage — roughly $15 million that does not represent the underlying run rate, with gross margin expected to step down in the third quarter as those items normalize. Customer growth of 3.8% and net sales per active customer up 1.9% are healthy but unspectacular. Meanwhile reported revenue actually shrank about 1% quarter over quarter. None of that is the profile of a company that should command a premium multiple to the market.

JPMorgan's own target math is the telling part. The $24 target rests on roughly 7x the firm's 2028 adjusted EBITDA estimate of about $1.2 billion — a mature, sub-10x EV/EBITDA-style valuation, not a growth premium. Even a bank that still likes the story is now pricing Chewy like a steady compounder rather than a hyper-grower.

That is not to dismiss what is genuinely strong here, because the balance sheet is where the factor stack gives Chewy real marks. The company carries net cash, with more cash than debt, and generated about $568 million of free cash flow over the trailing twelve months, up roughly 23% year over year. Return on invested capital is in the mid-30s, the adjusted EBITDA margin is being guided higher to 6.7%–6.8%, and Chewy bought back $200 million of stock in the quarter. As safety goes, this is a high-quality business — the profitability and cash-flow grades are real, and they are improving.

That is the full picture, and it matters for where this name belongs. This is not a broken company and not a value trap on a sales basis. It is a timing mismatch. The factor grade that has degraded is growth — decelerating organic sales, contracting sequential revenue, customers up less than 4% — and momentum has blown out negative at down 40% on the year, which is why the buyside finally tripped to Neutral. In a barbell, Chewy is a growth-sleeve position you hold only while growth proves itself, hedged with durable cash-flow names, not a conviction compounder you add to on the dip. The trigger that would change the case is visible and specific: organic sales re-accelerating back toward the high single digits without relying on one-time margin gifts. Until that shows up in the numbers, the downgrades are not a fresh shock. They are the market's multiple finally catching up to the growth — 40% of the way there and counting.